Product Information
ATACAND 32 MG TABLET is a brand product labeled by ANI Pharmaceuticals, Inc., priced at $9.9038 per EA under NDC 62559064390. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Jun 4, 1998. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Candesartan Cilexetil market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
32 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
62559064390
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CANDESARTAN CILEXETILApproval Type
New Drug (NDA)
FDA Application
NDA020838FDA Approved
6/4/1998
TE Code
AB
On Market Since
10/1/2018
Pharmacological Classes
Price Statistics
The NADAC for ATACAND 32 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.9038 per EA |
|---|---|
| All-time high | $9.9438 (Jun 11, 2025) |
| All-time low | $9.7264 (Aug 21, 2024) |
| 52-week high | $9.9124 |
| 52-week low | $9.8744 |
| Median price | $9.8750 |
| Average price | $9.8626 |
| Largest weekly change | +0.8% (Nov 20, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Candesartan Cilexetil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ATACAND 32 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATACAND 32 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $9.9038 per EA (NDC 62559064390), effective Sep 30, 2026.
How has the price of ATACAND 32 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATACAND 32 MG TABLET has held within roughly two percent of its current level. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for ATACAND 32 MG TABLET?
Since Apr 17, 2024, the NADAC for ATACAND 32 MG TABLET has ranged from a low of $9.7264 (Aug 21, 2024) to a high of $9.9438 (Jun 11, 2025), with a median of $9.8750 per EA.
Are there cheaper alternatives to ATACAND 32 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ATACAND 32 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ATACAND 32 MG TABLET?
ATACAND 32 MG TABLET (NDC 62559064390) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a brand product.